What is ADMA Biologics's D&A?

ADMA Biologics (ADMA) reported D&A of $1.8M in Q1 2026.

How has ADMA Biologics's D&A changed year-over-year?

ADMA Biologics's D&A decreased by 5.3% year-over-year, from $1.9M to $1.8M.

What is the long-term trend for ADMA Biologics's D&A?

Over 4 years (2021 to 2025), ADMA Biologics's D&A has grown at a 82.3% compound annual growth rate (CAGR), from $715K to $7.9M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

ADMA Biologics ADMA D&A

D&A at other companies

AbCellera Biologics Inc.ABCL

$6.84M+28.3%

ZymeworksZYME

$176K-89.1%

Quest DiagnosticsDGX

$37M-5.1%

Adaptive BiotechnologiesADPT

$419K0.0%

Charles River LaboratoriesCRL

$67.15M-44.2%

AmgenAMGN

——

Segments

By segment

See full

ADMA Bio Manufacturing$1.27M+9.7%

Plasma Collection Centers$565K-30.1%

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.02B-54.5%

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's D&A?: ADMA Biologics (ADMA) reported D&A of $1.8M in Q1 2026.
How has ADMA Biologics's D&A changed year-over-year?: ADMA Biologics's D&A decreased by 5.3% year-over-year, from $1.9M to $1.8M.
What is the long-term trend for ADMA Biologics's D&A?: Over 4 years (2021 to 2025), ADMA Biologics's D&A has grown at a 82.3% compound annual growth rate (CAGR), from $715K to $7.9M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.